7 results about "Macroglobulins" patented technology

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

The invention relates to application of alpha2-macroglobulin. The alpha2-macroglobulin can be used for promoting the interment effect of cells. The invention finds that the alpha2-macroglobulin can be used for promoting the intercellular effect of cells, and further can be possibly used in medicines for treating diseases such as atherosclerosis, inflammatory aging, tumors, chronic obstructive pulmonary disease and systemic lupus erythematosus caused by deficiency of intercellular function.

The present invention relates to protein prodrug constructs, e.g., protein fusion constructs, comprising complement 3 and pregnancy zone protein-like alpha-2-macroglobulin domain (CPAMD)-containing proteins (e.g., A2M) and one or more drugs, and acting as protease activatable prodrugs. The invention also relates to the release mechanism of the CPAMD protein and the development of multispecific drugs, such as bispecific drugs.

The present disclosure provides a pharmaceutical composition for the treatment of C1013G / CXCR4-associated macroglobulinemia in a subject, comprising an antibody or antigen-binding portion thereof that specifically binds to a CXCR4 receptor carrying a C1013G / CXCR4 mutation expressed on the surface of a macroglobulinemia cell. Also provided are methods (except for medical practices) for assessing whether macroglobulinemia Fahrenheit is likely to be suitable for treatment with an antibody or antigen-binding portion thereof that specifically binds to the CXCR4 receptor expressed on the surface of macroglobulinemia Fahrenheit cells, the method comprises evaluating whether a cell in a test tissue sample obtained from the macroglobulinemia Fahrenheit carries a C1013G mutation in the CXCR4 gene, and determining that the macroglobulinemia Fahrenheit is possibly suitable for treatment if it is determined that the macroglobulinemia Fahrenheit carries the C1013G mutation in the CXCR4 gene, and a kit for use in the treatment of C1013G / CXCR4 related macroglobulinemia of Fahrenheit. The pharmaceutical composition disclosed by the invention can be used for effectively treating the macroglobulinemia of Fahrenheit related to C1013G / CXCR4.

The present invention relates to a protein fusion construct comprising a protein prodrug construct, for example, a complement 3- and pregnancy-related protein-like alpha-2-macroglobulin domain-containing (CPAMD) protein (e.g., A2M) and one or more drugs, which functions as a protease-activatable prodrug. The present invention further relates to the release mechanism from the CPAMD protein and the development of multispecific drugs such as bispecificity.

Provided are modified alpha-2-macroglobulin (A2M) proteins with altered binding to clearance receptors such as LRP1 and GRP78, compositions comprising protein complexes of the modified A2M proteins with serine protease proteins such as porcine pancreatic elastase (PPE), compositions comprising protein complexes of alpha-2-macroglobulin-like protein 1 (A2ML1) with serine protease proteins, and related methods of use and manufacture for treating diseases such as cancers.

A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.